Data and Database Management Software
Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform
Share:
Genedata Biologics integrates and streamlines workflows for protein therapeutics RD groups across multiple Boehringer Ingelheim sites
Basel, Switzerland – Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Boehringer Ingelheim has chosen Genedata Biologics™ as their global biologics RD workflow and data management platform. The Genedata Biologics platform will support multiple Boehringer Ingelheim RD groups in the US and Europe, including Lead Identification and Screening, Lead Optimization and Engineering, and Protein Production groups across Boehringer Ingelheim's New Biological Entities (NBEs) centers.
"Our Biotherapeutics Research division required a central system to support the complex and interconnected workflows in our large-molecule discovery units," said Dr. Miguel Teodoro, Head of IT Research at Boehringer Ingelheim. "We undertook a thorough selection process to find the best antibody workflow platform and Genedata Biologics was the obvious choice. We believe Genedata Biologics will help us to accelerate our antibody discovery programs as we develop the next generation of biologics drugs."
Genedata Biologics streamlines biopharma discovery operations by integrating workflows and data from diverse research processes and antibody discovery platforms, such as phage and yeast display, hybridomas, and B-cells, as well as downstream expression, purification, and analytics. Genedata Biologics reduces data capture and reporting time by 50% and significantly improves candidate quality through standardized and automated data integrity analysis. In addition, the system greatly increases experimental throughput by directly interfacing with laboratory automation instruments.
"We are excited that Boehringer Ingelheim, a global leader in biopharmaceuticals, has chosen Genedata Biologics for data management and processing to support their New Biological Entities units," said Dr. Othmar Pfannes, CEO of Genedata. "This latest addition to the rapidly growing list of leading biopharmas partnering with Genedata proves again the value of our platform, which speeds up the discovery, optimization, and development of novel biopharmaceuticals. We are committed to continuing to expand the platform to meet the rapidly developing new requirements in this exciting field."
About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
www.genedata.com
Contacts
Allison Kurz
Genedata
Public Relations
Phone: +41 61 511 8459
pr@genedata.com
Genedata AGÂ
Margarethenstrasse 38
4053 Basel, SwitzerlandÂ
Tel. +41 61 511 8400Â
Fax +41 61 511 8484
Genedata Inc.Â
750 Marrett Road
One Cranberry Hill
Suite 403
Lexington, MA 02421Â
Tel. +1 781 357 4755Â
Fax +1 781 357 4770
Genedata Inc.Â
109 Stevenson Street
4th Floor
San Francisco, CA 94105Â
Tel. +1 877 436 3872Â
Fax +1 415 970 6631
Genedata GmbHÂ
Fürstenrieder Strasse 281
81377 Munich, GermanyÂ
Tel. +49 89 4581 9010Â
Fax +49 89 4581 9015
Genedata KKÂ
1-7-11-408
Higashi-Gotanda
Shinagawa-Ku
Tokyo 141-0022, JapanÂ
Tel. +81 3 6721 7261Â
Fax +81 3 6721 7262
www.genedata.comÂ
pr@genedata.com
